___

• Kaynaklar 1.N J Shaw. Arch Dis Child Educ Pract Ed 2007;92:ep169–ep175. doi: 10.1136/adc.2006.105791 2.Goulding A, Cannan R, Williams SM, et al. BMD in girls withforearm fractures. J Bone Miner Res 1998;13:143–8. 3.Clark EM, Ness AR, Bishop NJ, et al. Association between bonemass and fractures in children: a prospective cohort study. JBone Miner Res 2006;21:1489–95. 4.Allgrove J, Shaw NJ (eds): Calcium and Bone Disorders inChildren and Adolescents. 2nd, revised edition. Endocr Dev.Basel, Karger, 2015, vol 28, pp 176–195 (DOI: 10.1159/000381045) 5.Morello R, Bertin TK, Chen Y, et al. CRTAP is required forprolyl 3-hydroxylation and mutations cause recessive osteo-genesis imperfecta. Cell 2006;127:291–304. 6.Hartikka H, Makitie O, Mannikko M, et al. Heterozygous mu-tations in the LDL receptor related protein 5 (LRP5) gene areassociated with primary osteoporosis in children. J Bone Mi-ner Res 2005;20:783–9. 7.Gong Y, Slee RB, Fukai N, et al. LDL receptor-related pro-tein 5 (LRP5) affects bone accrual and eye development. Cell2001;107:513–23. 8.Mäkitie, O. Nat. Rev. Rheumatol. 9, 465–475 (2013); publis-hed online 16 April 2013; doi:10.1038/nrrheum.2013.45 9.Stevenson RD, Conaway M, Barrington JW, et al. Fracturerate in children with cerebral palsy. Pediatr Rehabil2006;9:396–403. 10.Binkley T, Johnson J, Vogel L, et al. Bone measurements byperipheral quantitative computed tomography(pQCT) inchildren with cerebral palsy. J Pediatr 2005;147:791–6. 11.Larson CM, Henderson RC. Bone mineral density and frac-tures in boys with Duchenne muscular dystrophy. J PediatrOrthop 2000;20:71–4. 12.Sylvester FA, Davis PM, Wyzga N, et al. Are activated T cellsregulators of bone metabolism in children with Crohn disea-se? J Pediatr 2006;148:461–6. 13.Thearle M, Horlick M, Bilezikian JP, et al. Osteoporosis: anunusual presentation of childhood Crohn’s disease. J Clin En-docrinol Metab 2000;85:2122–6. 14.Bielinski BK, Darbyshire PJ, Mathers L, et al. Impact of di-sordered puberty on bone density in b thalassaemia major. BrJ Haemat 2003;120:353–8. 15.Gafni R, Baron J. Overdiagnosis of osteoporosis in childrendue to misinterpretation of dual-energy X-ray absorptiometry(DEXA). J Pediatr 2004;144:253–7. 16.Homik J, Suarez-Almazor ME, Shea B, et al. Calcium and vi-tamin D for corticosteroid-induced osteoporosis. CochraneDatabase Syst Rev 2000;2:CD000952. 17.Caulton JM, Ward KA, Alsop CW, et al. A randomised con-trolled trial of standing programme on bone mineral densityin non-ambulant children with cerebral palsy. Arch Dis Child2004;89:131–5. 18.Ward K, Alsop C, Caulton J, et al. Low magnitude mechani-cal loading is osteogenic in children with disabling conditi-ons. J Bone Miner Res 2004;19:360–9 19.Glorieux FH, Bishop NJ, Plotkin H, et al. Cyclic administra-tion of pamidronate in children with severe osteogenesis im-perfecta. N Engl J Med 1998;339:947–52. 20.Grissom LE, Kecskemethy HH, Bachrach SJ, et al. Bone den-sitometry in pediatric patients treated with pamidronate. Pe-diatr Radiol 2005;35:511–17. 21.7 Sakkers R, Kok D, Engelbert R, et al. Skeletal effects andfunctional outcome with olpadronate in children with osteo-genesis imperfecta: a 2 year randomised placebo-controlledstudy. Lancet 2004;363:1427–31. 22.Grissom LE, Kecskemethy HH, Bachrach SJ, et al. Bone den-sitometry in pediatric patients treated with pamidronate. Pe-diatr Radiol 2005;35:511–17. 23.Munns CF, Rauch F, Zeitlin L, et al. Delayed osteotomy butnot fracture healing in pediatric osteogenesis imperfecta pa-tients receiving pamidronate. J Bone Miner Res2004;19:1779–86 24.Papapoulos SE, Cremers SCLM. Prolonged bisphosphonaterelease after treatment in children. N Engl J Med 2007;356:1075–76. 25.Ward KA, Adams JE, Freemont TJ, et al. Can bisphosphona-te treatment be stopped in a growing child with skeletal fra-gility? Osteoporos Int 2007;18:1137–40. 26.Bilezikian JP. Osteonecrosis of the jaw: do bisphosphonatespose a risk? N Engl J Med 2006;355:2278–81. 43 27.Whyte MP, Wenkert D, Clements KL, et al. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003;349:457–63.